Top

Annals of Hematology

Published in:

01-03-2013 | Letter to the Editor

Pericentric chromosome 8 inversion, inv(8)(p11.2q22), associated with RUNX1/RUNX1T1 rearrangement in acute myeloid leukemia

Authors: Katsuya Yamamoto, Atsuo Okamura, Kimikazu Yakushijin, Hiroshi Matsuoka, Hironobu Minami

Published in: Annals of Hematology | Issue 3/2013

Excerpt

Dear Editor, …

Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Bloomfield CD (2008) Acute myeloid leukaemia with t(8;21)(q22;q22); RUNX1-RUNX1T1. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. International Agency for Research on Cancer, Lyon, pp 110–111

Anelli L, Albano F, Zagaria A, Liso A, Cuneo A, Mancini M, Liso V, Rocchi M, Specchia G (2005) Pericentric chromosome 8 inversion associated with the 5′RUNX1/3′CBFA2T1 gene in acute myeloid leukemia cases. Ann Hematol 84:245–249PubMedCrossRef

Mitelman F, Johansson B, Mertens F (eds) (2012). Mitelman database of chromosome aberrations and gene fusions in cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed July 25, 2012

Peterson LF, Zhang DE (2004) The 8;21 translocation in leukemogenesis. Oncogene 23:4255–4262PubMedCrossRef

Slater RM, Behrendt H, De Waal FC (1983) Chromosome studies on acute nonlymphocytic leukaemia in children. Pediatr Res 17:398–405PubMedCrossRef

Title: Pericentric chromosome 8 inversion, inv(8)(p11.2q22), associated with RUNX1/RUNX1T1 rearrangement in acute myeloid leukemia
Authors: Katsuya Yamamoto
Atsuo Okamura
Kimikazu Yakushijin
Hiroshi Matsuoka
Hironobu Minami
Publication date: 01-03-2013
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 3/2013
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-012-1559-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 3/2013

Survival benefit with salvage radiotherapy for patients with locoregionally recurrent extranodal NK/T cell lymphoma, nasal type

Hydroxyurea treatment in β-thalassemia patients: to respond or not to respond?

Acquired deficiency of coagulation factor XIII—possible evidence for a new link between coagulation and infection from a case

Early death in patients diagnosed with non-Hodgkin’s lymphoma

Prognostic significance of expression levels of stem cell regulators MSI2 and NUMB in acute myeloid leukemia

A novel large-sized BCR-ABL transcript in a case of chronic myeloid leukaemia characterised by a favourable clinical course

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials